{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T08:48:13Z","timestamp":1788684493138,"version":"build-2803163510"},"reference-count":185,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119670","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:58:02Z","timestamp":1781798282000},"page":"119670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors"],"prefix":"10.1016","volume":"201","author":[{"given":"Sisi","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongmin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhichao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tang","family":"Siyao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayoung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-3260","authenticated-orcid":false,"given":"Wootae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119670_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1101\/sqb.2000.65.127","article-title":"Repair of endogenous DNA damage","volume":"65","author":"Lindahl","year":"2000","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cell.2017.01.002","article-title":"Endogenous DNA damage as a source of genomic instability in cancer","volume":"168","author":"Tubbs","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119670_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell."},{"key":"10.1016\/j.biopha.2026.119670_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell."},{"key":"10.1016\/j.biopha.2026.119670_bib6","article-title":"The interplay between chromatin remodeling and DNA double-strand break repair: implications for cancer biology and therapeutics","volume":"1880","author":"He","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1126\/science.1108297","article-title":"ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex","volume":"308","author":"Lee","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119670_bib8","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Matsuoka","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119670_bib9","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.1083430","article-title":"Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes","volume":"300","author":"Zou","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119670_bib10","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.dnarep.2014.02.020","article-title":"DNA-PK: a dynamic enzyme in a versatile DSB repair pathway","volume":"17","author":"Davis","year":"2014","journal-title":"DNA Repair. (Amst. )"},{"key":"10.1016\/j.biopha.2026.119670_bib12","doi-asserted-by":"crossref","first-page":"a012740","DOI":"10.1101\/cshperspect.a012740","article-title":"Repair of strand breaks by homologous recombination","volume":"5","author":"Jasin","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib13","doi-asserted-by":"crossref","first-page":"9558","DOI":"10.1074\/jbc.M808906200","article-title":"Human CtIP mediates cell cycle control of DNA end resection and double strand break repair","volume":"284","author":"Huertas","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119670_bib14","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s12276-020-00519-1","article-title":"DNA end resection and its role in DNA replication and DSB repair choice in mammalian cells","volume":"52","author":"Zhao","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","article-title":"The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway","volume":"79","author":"Lieber","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.biopha.2026.119670_bib16","doi-asserted-by":"crossref","first-page":"a012609","DOI":"10.1101\/cshperspect.a012609","article-title":"Nucleotide excision repair in eukaryotes","volume":"5","author":"Sch\u00e4rer","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib17","doi-asserted-by":"crossref","first-page":"a012633","DOI":"10.1101\/cshperspect.a012633","article-title":"Postreplicative mismatch repair","volume":"5","author":"Jiricny","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.dnarep.2014.03.030","article-title":"Base excision repair: a critical player in many games","volume":"19","author":"Wallace","year":"2014","journal-title":"DNA Repair. (Amst. )"},{"key":"10.1016\/j.biopha.2026.119670_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrm3719","article-title":"Double-strand break repair: 53BP1 comes into focus","volume":"15","author":"Panier","year":"2014","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrc3088","article-title":"DNA interstrand crosslink repair and cancer","volume":"11","author":"Deans","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119670_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell. Rep."},{"key":"10.1016\/j.biopha.2026.119670_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib29","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib31","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib32","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119670_bib33","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119670_bib34","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib36","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib38","unstructured":"Mirza M.R., et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian."},{"key":"10.1016\/j.biopha.2026.119670_bib39","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3)","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119670_bib40","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119670_bib42","article-title":"First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic tumors","author":"Ulahannan","year":"2025","journal-title":"Presented American Association Cancer Research (AACR) Annual Meeting"},{"key":"10.1016\/j.biopha.2026.119670_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D'Andrea","year":"2018","journal-title":"DNA Repair. (Amst. )"},{"key":"10.1016\/j.biopha.2026.119670_bib45","unstructured":"Konstantinopoulos P.A., Ceccaldi R., Shapiro G.I., D'Andrea A.D. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer."},{"key":"10.1016\/j.biopha.2026.119670_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119670_bib47","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-genet-110410-132435","article-title":"Double-strand break end resection and repair pathway choice","volume":"45","author":"Symington","year":"2011","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.biopha.2026.119670_bib49","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2026.119670_bib50","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/19491034.2016.1267092","article-title":"The BRCA1 ubiquitin ligase function sets a new trend for remodelling in DNA repair","volume":"8","author":"Densham","year":"2017","journal-title":"Nucleus"},{"key":"10.1016\/j.biopha.2026.119670_bib52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature01230","article-title":"Insights into DNA recombination from the structure of a RAD51-BRCA2 complex","volume":"420","author":"Pellegrini","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib53","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of 'BRCAness' in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib54","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","article-title":"Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2","volume":"22","author":"Xia","year":"2006","journal-title":"Mol. Cell."},{"key":"10.1016\/j.biopha.2026.119670_bib55","unstructured":"Loveday C., et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer."},{"key":"10.1016\/j.biopha.2026.119670_bib56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13058-018-0935-9","article-title":"BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer","volume":"20","author":"Weber-Lassalle","year":"2018","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biopha.2026.119670_bib57","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib58","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib59","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41586-023-06219-w","article-title":"Structural insights into BCDX2 complex function in homologous recombination","volume":"619","author":"Rawal","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib60","doi-asserted-by":"crossref","first-page":"11738","DOI":"10.1093\/nar\/gkae770","article-title":"Mechanism of BCDX2-mediated RAD51 nucleation on short ssDNA stretches and fork DNA","volume":"52","author":"Akita","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119670_bib62","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41419-023-06267-0","article-title":"Liquid-liquid phase separation in DNA double-strand breaks repair","volume":"14","author":"Liu","year":"2023","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.biopha.2026.119670_bib63","article-title":"PARP1 condensates differentially partition DNA repair proteins and enhance DNA ligation","author":"Suskiewicz","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2026.119670_bib64","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119670_bib65","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1128\/MCB.23.16.5706-5715.2003","article-title":"Pathways of DNA double-strand break repair during the mammalian cell cycle","volume":"23","author":"Rothkamm","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib66","unstructured":"Jiang W., et al. Differential phosphorylation of DNA-PKcs regulates the interplay between end-processing and end-ligation during nonhomologous end-joining. Mol Cell."},{"key":"10.1016\/j.biopha.2026.119670_bib67","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0092-8674(02)00671-2","article-title":"Hairpin opening and overhang processing by an Artemis\/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination","volume":"108","author":"Ma","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119670_bib68","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","article-title":"TCGA Pan-Cancer Atlas. Comprehensive characterization of cancer driver genes and mutations","volume":"173","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119670_bib69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2199-11-18","article-title":"DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression","volume":"11","author":"An","year":"2010","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005814","article-title":"Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors","volume":"5","author":"Riabinska","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib71","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijrobp.2016.10.018","article-title":"Ku70, Ku80, and sClusterin: a cluster of predicting factors for response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer","volume":"97","author":"Pucci","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.biopha.2026.119670_bib72","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cell.2007.10.005","article-title":"A backup DNA repair pathway moves to the forefront","volume":"131","author":"Nussenzweig","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119670_bib73","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S1097-2765(01)00408-7","article-title":"DNA ligase IV mutations identified in patients with developmental delay and immunodeficiency","volume":"8","author":"O\u2032Driscoll","year":"2001","journal-title":"Mol. Cell."},{"key":"10.1016\/j.biopha.2026.119670_bib74","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","article-title":"AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity","volume":"10","author":"Fok","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119670_bib75","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nrm2549","article-title":"Transcription-coupled DNA repair: two decades of progress and surprises","volume":"9","author":"Hanawalt","year":"2008","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib76","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/emboj.2009.49","article-title":"Coordination of dual incision and repair synthesis in human nucleotide excision repair","volume":"28","author":"Staresincic","year":"2009","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2026.119670_bib77","doi-asserted-by":"crossref","first-page":"9990","DOI":"10.1093\/nar\/gks818","article-title":"DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy","volume":"40","author":"McNeil","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119670_bib78","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib79","first-page":"1468","article-title":"Preclinical in vivo validation of the RAD51 test as a predictive biomarker for PARPi response in ovarian cancer","volume":"82","author":"Pellegrino","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119670_bib80","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1200\/JCO.2016.68.1841","article-title":"Randomized prospective biomarker trial of ERCC1 for comparing platinum-based chemotherapy in advanced NSCLC: ERCC1 Trial (ET)","volume":"35","author":"Lee","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib81","first-page":"163","article-title":"ERCC1 expression and platinum resistance in ovarian and colorectal cancer","volume":"137","author":"Strickland","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib82","series-title":"GeneReviews","article-title":"Xeroderma pigmentosum","author":"Kraemer","year":"2016"},{"key":"10.1016\/j.biopha.2026.119670_bib83","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib84","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib85","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ng.3557","article-title":"Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors","volume":"48","author":"Kim","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2026.119670_bib86","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119670_bib87","doi-asserted-by":"crossref","first-page":"a012583","DOI":"10.1101\/cshperspect.a012583","article-title":"Base excision repair","volume":"5","author":"Krokan","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib88","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib89","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/ng1834","article-title":"CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer","volume":"38","author":"Weisenberger","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2026.119670_bib90","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119670_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","author":"Bonneville","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib92","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature24673","article-title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","volume":"552","author":"Germano","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib93","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119670_bib94","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2026.119670_bib95","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell. Rep."},{"key":"10.1016\/j.biopha.2026.119670_bib96","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib97","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","article-title":"The shieldin complex mediates 53BP1-dependent DNA repair","volume":"560","author":"Noordermeer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib98","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119670_bib99","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-genet-112414-054722","article-title":"Eukaryotic mismatch repair in relation to DNA replication","volume":"49","author":"Kunkel","year":"2015","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.biopha.2026.119670_bib100","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.dnarep.2004.06.006","article-title":"Mismatch repair and DNA damage signalling","volume":"3","author":"Stojic","year":"2004","journal-title":"DNA Repair. (Amst. )"},{"key":"10.1016\/j.biopha.2026.119670_bib101","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc3878","article-title":"Milestones of Lynch syndrome: 1895-2015","volume":"15","author":"Lynch","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib102","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/1535-7163.679.3.6","article-title":"Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition","volume":"3","author":"Wang","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119670_bib103","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/aje\/kwi318","article-title":"Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review","volume":"162","author":"Hung","year":"2005","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.biopha.2026.119670_bib104","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41556-021-00723-9","article-title":"ASTE1 promotes shieldin-complex-mediated DNA repair by attenuating end resection","volume":"23","author":"Zhao","year":"2021","journal-title":"Nat. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nature07955","article-title":"CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle","volume":"459","author":"Yun","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib106","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119670_bib107","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119670_bib108","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/ars.2008.2194","article-title":"Bhakat KK. The many functions of APE1\/Ref-1: not only a DNA repair enzyme","volume":"11","author":"Tell","year":"2009","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.biopha.2026.119670_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2019.102664","article-title":"XRCC1 protein; form and function","volume":"81","author":"Caldecott","year":"2019","journal-title":"DNA Repair. (Amst. )"},{"key":"10.1016\/j.biopha.2026.119670_bib110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.gpb.2016.05.001","article-title":"Functions of PARylation in DNA damage repair pathways","volume":"14","author":"Wei","year":"2016","journal-title":"Genom. Proteom. Bioinforma."},{"key":"10.1016\/j.biopha.2026.119670_bib111","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib112","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119670_bib113","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1038\/sj.emboj.7601277","article-title":"New functions of XPC in the protection of human skin cells from oxidative damage","volume":"25","author":"D'Errico","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2026.119670_bib114","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Matsuoka","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119670_bib115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The ATM protein kinase: regulating the cellular response to genotoxic stress, and more","volume":"14","author":"Shiloh","year":"2013","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119670_bib116","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119670_bib117","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119670_bib118","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","article-title":"ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment","volume":"25","author":"Dillon","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119670_bib119","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc.2015.12","article-title":"A panoply of errors: polymerase proofreading domain mutations in cancer","volume":"16","author":"Rayner","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib120","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1172\/JCI84940","article-title":"Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer","volume":"126","author":"Mehnert","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2026.119670_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119670_bib122","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: the convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib123","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/s41591-019-0462-y","article-title":"Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer","volume":"25","author":"Kather","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib124","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41388-017-0120-0","article-title":"Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production","volume":"37","author":"Konno","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119670_bib125","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41588-018-0179-8","article-title":"Copy number signatures and mutational processes in ovarian carcinoma","volume":"50","author":"Macintyre","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2026.119670_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib127","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard","year":"2015","journal-title":"Biomark. Res."},{"key":"10.1016\/j.biopha.2026.119670_bib128","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib129","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119670_bib130","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119670_bib131","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib132","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib133","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1038\/s41598-020-59671-3","article-title":"Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma","volume":"10","author":"Takaya","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119670_bib134","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/djy085","article-title":"Biomarkers for homologous recombination deficiency in cancer","volume":"110","author":"Hoppe","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2026.119670_bib135","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119670_bib136","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119670_bib137","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/PO.19.00345","article-title":"Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity","author":"Sokol","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib138","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw148","article-title":"Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer","volume":"108","author":"Ter Brugge","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2026.119670_bib139","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib140","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","article-title":"A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","volume":"49","author":"Polak","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2026.119670_bib141","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","article-title":"Detecting the mutational signature of homologous recombination deficiency in clinical samples","volume":"51","author":"Gulhan","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2026.119670_bib142","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nature11935","article-title":"Replication stress links structural and numerical cancer chromosomal instability","volume":"494","author":"Burrell","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib143","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib144","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1913-9","article-title":"Patterns of somatic structural variation in human cancer genomes","volume":"578","author":"Li","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib145","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119670_bib146","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib147","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib148","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1002\/cncr.30808","article-title":"The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer","volume":"123","author":"Pomerantz","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib149","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1158\/1078-0432.CCR-10-1027","article-title":"A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer","volume":"16","author":"Graeser","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119670_bib150","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/1078-0432.CCR-18-0063","article-title":"Functional ex vivo assay reveals homologous recombination deficiency in breast cancer beyond BRCA gene defects","volume":"24","author":"Meijer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119670_bib151","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib152","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119670_bib153","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib154","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119670_bib155","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/cancers12030687","article-title":"ATM-deficient cancers provide new opportunities for precision oncology","volume":"12","author":"Jette","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119670_bib156","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119670_bib157","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib158","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119670_bib159","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","article-title":"DNA damage and repair biomarkers of immunotherapy response","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119670_bib160","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119670_bib161","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib162","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"Oaknin","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2026.119670_bib163","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib164","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1038\/s41467-019-10460-1","article-title":"Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence","volume":"10","author":"Fleury","year":"2019","journal-title":"Nat. Commun."},{"issue":"492","key":"10.1016\/j.biopha.2026.119670_bib165","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4508","article-title":"Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51","volume":"11","author":"Kaplan","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119670_bib166","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10555-018-9768-3","article-title":"Cancer-associated fibroblasts as key regulators of the breast cancer microenvironment","volume":"37","author":"Houthuijzen","year":"2018","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.biopha.2026.119670_bib167","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.aau0447","article-title":"Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response","volume":"364","author":"Mandal","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119670_bib168","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/1940-6207.CAPR-11-0288","article-title":"Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing","volume":"5","author":"Bartley","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.biopha.2026.119670_bib169","first-page":"293","article-title":"Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome","volume":"10","author":"Shia","year":"2008","journal-title":"Part. I. Util. Immunohistochem. J. Mol. Diagn."},{"key":"10.1016\/j.biopha.2026.119670_bib170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib171","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib172","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib173","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"29","author":"Plon","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.biopha.2026.119670_bib174","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib175","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2026.119670_bib176","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","article-title":"Detecting the mutational signature of homologous recombination deficiency in clinical samples","volume":"51","author":"Gulhan","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2026.119670_bib177","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119670_bib178","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119670_bib179","first-page":"3579","article-title":"The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts","volume":"58","author":"Vaisman","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119670_bib180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119670_bib181","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.celrep.2018.03.046","article-title":"Machine learning detects pan-cancer ras pathway activation in The Cancer Genome Atlas","volume":"23","author":"Way","year":"2018","journal-title":"Cell. Rep."},{"key":"10.1016\/j.biopha.2026.119670_bib182","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41591-019-0548-6","article-title":"Do no harm: a roadmap for responsible machine learning for health care","volume":"25","author":"Wiens","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib183","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119670_bib184","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119670_bib185","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119670_bib186","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","article-title":"Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:37:47Z","timestamp":1784529467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":185,"alternative-id":["S0753332226007067"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119670","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119670"}}